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Background/aim: Paget’s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1%–3% of all
primary breast tumors. We aimed to evaluate and compare the clinicopathological features and clinical outcome of PD accompanied
by in situ carcinoma and invasive cancer.
Materials and methods: We used the archive of our pathology laboratory retrospectively for age, sex, history of surgery, histopathological
findings, treatment modalities, and follow-up information. We used the Kaplan–Meier method for survival analysis.
Results: There were 46 female patients diagnosed with PD. In 39 (84.7%) patients, invasive carcinoma accompanied PD, while 7 (15.3%)
patients had ductal carcinoma in situ. The median age at diagnosis was 53.5 years. The median follow-up period was 47 months. Of the
39 invasive carcinoma, 10 (25.6%) died during the follow-up period. Invasive ductal carcinoma group had a mean overall survival of rate
of 57.8 ± 6.6 months. According to univariate analysis, only the tumor type was found to impact overall survival (p < 0.001).
Conclusions: The current study displayed the tumor type as the only parameter affecting overall survival in the invasive carcinoma
group. Although it was not statistically significant, breast cancers accompanied by PD were found to be predominantly advanced stage
tumors, high grade, hormone receptor negative, and HER2 positive.
Key words: Paget’s disease, breast carcinoma, pathology, molecular subtype, immunohistochemistry

1. Introduction
Paget’s disease (PD) of the breast is a very rare presentation
of breast malignancy, accounting for 1%–3% of all
primary breast tumors [1-3]. PD of the breast emerges
as erythematous and ulcerated nipple. As these changes
are frequently diagnosed as dermatitis or eczema, the
diagnosis and treatment are often delayed. The diagnosis
must be confirmed with a biopsy of the nipple-areola
complex [4-6]. It is characterized histopathologically by
the infiltration of the nipple epidermis with relatively
large round tumor cells with clear cytoplasm and vesicular
nuclei with hyperchromatic nuclei [7]. There are two
theories on the hypothesis of the nature and origin of
PD: in situ malignant transformation theory and the
epidermotropic theory. The transformation theory tells us
that Paget cells are transformed from keratinocytes of the
epidermis of the nipple. The second theory assumes that

Paget cells are ductal carcinoma cells that have migrated
from the underlying breast ducts to the epidermis of the
mammary gland. Regardless of the origin the Paget cells,
this is still debated [4,8,9]. Most cases have an underlying
in situ or invasive breast carcinoma and some cases appear
without any underlying neoplasia [4,5,10]. In different
series, while ductal carcinoma in situ (DCIS) associated
with Paget’s disease is frequently comedo type, invasive
ductal carcinoma is the most common type of invasive
cancer associated with PD [4,8]. Coexistence of PD with
invasive cancer was found to be associated with poor
prognosis, and various clinicopathological parameters
were implicated in the studies conducted to reveal the
reason for this [8,10].
In recent years, in line with the advances in diagnosis
and treatment of breast cancer, there have been significant
developments in pathological diagnostic criteria of PD and
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its surgical approach. Considering these developments,
we aimed to evaluate and compare the clinicopathologic
characteristics and clinical outcome of PD accompanied
by in situ carcinoma and invasive cancer.
2. Materials and methods
2.1. Case selection
We searched the archive of our pathology laboratory
retrospectively and we collected the clinical information
from our hospital’s electronic database. We selected 54
patients diagnosed with PD between December 2006 and
June 2017. We excluded 3 patients whose data were not
available and 5 patients who had metastasis. We included
46 patients in our study. A detailed histopathologic review
was performed by three pathologists to confirm the
diagnosis of PD. While the diagnosis of PD in 37 patients
was based on the skin biopsy and/or mastectomy material
performed in our hospital, the diagnosis of 9 patients was
made in consultation blocks. We contacted the patients
diagnosed by consultation blocks and we obtained the
necessary information from the patients themselves and/
or their relatives. We obtained information such as age,
sex, history of surgery, histopathologic findings, treatment
modalities, and follow-up information. The cases were
divided into two groups as PD-DCIS and PD-Invasive
carcinoma (IC) according to the pathology accompanying
Paget’s disease. Age, laterality, tumor location, tumor size,
tumor type and type of surgery were regarded as clinical
characteristics, while tumor grade, ER, PR, HER2 status,
Ki-67, molecular subtype and lymph node status were
regarded as histopathological characteristics; their effect
on overall survival (OS) was investigated.
The study protocol was approved by the institutional
ethics committee of Izmir Katip Celebi University
(22.10.2020-1008).
2.2. Histopathological evaluation
During histopathological examination, presence of
underlying tumor, tumor diameter, tumor type, in situ
carcinoma type, presence of lymph node metastasis,
histological type of tumor and tumor multifocality
were recorded. Immunohistochemical stainings were
reevaluated. All antibodies were provided from Dako
Cytomation (Denmark) and they were ready to use. In
order to determine the antibody distribution pattern,
percentage of positive cells and intensity of reactive tumor
cells were scored semiquantitatively for estrogen receptor
(ER) and progesteron receptor (PR). A positive result was
considered if at least 1% of cells have a nuclear expression
[11]. Human epidermal growth factor receptor 2 (HER2)
was scored using the new recommendations of ASCO/
CAP Guidelines. Cases with immunohistochemically 2 +
score were further analyzed for HER2 gene amplification
by fluorescence in situ hybridization technique [12]. Less

than 14% positive nuclear staining for Ki-67 antibody
was considered low expression [13]. p53 was considered
positive if more than 10% of tumor nuclei were stained.
In terms of immunohistochemical expressions of ER, PR,
HER2 and Ki-67, the tumor was classified into following
molecular subtypes: Luminal A (ER+ and/or PR+, HER2-,
low Ki-67), Luminal B (ER+ and/or PR+, HER2+, any Ki67 or ER+ and/or PR+, HER2-, high Ki-67), HER2 rich
(ER-, PR-, HER2+), triple negative (ER-, PR-, HER2-) [14].
For tumor location, physical examination and gross
pathology assessment were evaluated together. Invasive
tumors were graded according to the modified ScarffBloom-Richardson grading system. For in situ carcinomas,
nuclear grading was noted as mild, moderate, or severe.
Comedo necrosis was also recorded in all cases. The staging
was performed according to American Joint Committee
on Cancer 8th edition [14].
2.3. Statistical analysis
Survival analysis was done by using the Kaplan–Meier
method. Comparison of the variables of the survival times
of the factors between the categories was evaluated by the
log-rank Mantel–Cox test. OS was defined as the duration
from initial diagnosis to death due to any cases. The data
were evaluated via SPPS 20 (IBM Corp. Released 2011.
IBM SPSS Statistics for Windows, Version 20.0. Armonk,
NY: IBM Corp.). p < 0.05 and p < 0.01 were taken as
significance levels.
3. Results
There were 46 patients diagnosed with PD, all were female.
Invasive carcinoma accompanied PD in 39 (84.7%) patients,
while DCIS was detected in 7 (15.3%) patients. Most of
the invasive tumor type was invasive ductal carcinoma
(IDC) (76.9%), eight patients with mixed type had invasive
ductal cancer accompanied by invasive papillary, invasive
lobular, invasive micropapillary and glycogen-rich type.
One patient (2.6%) was with pure apocrine features. All in
situ carcinomas were ductal carcinoma in situ. The median
age at diagnosis was 53.5 (range: 30–80) years, which was
45.4 and 54.9 in DCIS group and IC group, respectively.
Most of the patients had unifocal tumor either at central or
peripheral location. Locations of IC and DCIS are shown
in Table 1. While the diagnosis was made by skin biopsies
taken from the areola in 11 patients, mastectomy specimen
displayed the diagnosis in 35 patients.
In terms of surgical techniques, modified radical
mastectomy (MRM), breast conserving surgery (BCS),
simple mastectomy, and nipple areola complex (NAC)
resection were performed in 32, 7, 6, and 1 patient,
respectively. Modified radical mastectomy in the IC
group and BCS in the DCIS group were the preferred
surgical methods. Sentinel lymph node biopsy (SLNB)
was performed in 5 of 39 patients diagnosed with IC, and
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Table 1. Clinical characteristics of the patients.
PD-DCIS
n = 7 (%)

PD-IC
n = 39 (%)

<40

2 (28.6)

7 (18)

40–59

5 (71.4)

15 (38.4)

≥60

0

17 (43.6)

Left

4 (57.1)

22 (56.4)

Right

3 (42.9)

17 (43.6)

Central

4 (57.1)

10 (25.6)

Unifocal peripheral

0

12 (30.8)

Multicentric

2 (28.6)

12 (30.8)

Unknown

1 (14.3)

5 (12.8)

MRM

0

32 (82)

BCS + SLNB

3 (42.9)

2 (5.1)

BCS + ALND

1 (14.3)

0

Simple mastectomy +SLNB

2 (28.5)

3 (7.7)

Sımple mastectomy

0

1 (2.5)

NAC resection

1 (14.3)

0

NAC biopsy

0

1 (2.5)

0–2 cm

5 (71.4)

15 (38.4)

2.1–5 cm

1(14.3)

14 (35.9)

>5 cm

0

7 (18)

Unknown

1 (14.3)

3 (7.7)

Invasive ductal carcinoma

-

30 (76.9)

Mixed tumor

-

8 (20.5)

Apocrine tumor

-

1 (2.6)

Ductal carcinoma in situ

7 (100)

-

Characteristic
Age (years)

Laterality

Tumor location

Type of surgery

Tumor size

Tumor type

PD-DCIS = Paget’s disease-ductal carcinoma in situ; PD-IC =
Paget’s disease-invasive carcinoma; MRM = modified radical
mastectomy; BCS = breast-conserving surgery; SLNB = sentinel
lymph node biopsy; ALNB = axillary lymph node dissection;
NAC = nipple areola complex.

axillary lymph node dissection (ALND) was performed
in 32 patients. While SLNB was negative in 4 patients,
metastatic lymph node was detected in one patient and
a subsequent ALND was performed. Three of 32 patients
who underwent ALND did not have metastases and the
remaining 29 patients had metastatic lymph nodes. While
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SLNB was performed in 4 of 7 patients with DCIS, ALND
was performed in 2 patients, and axillary sampling was not
performed in one patient. Lymph node metastasis was not
detected in this group. Surgical procedures for all patients,
except for one patient who refused the surgical treatment
after biopsy, are summarized in Table 1.
The data of histologic tumor diameter was available
in 36 of 39 invasive carcinomas, and the mean tumor
diameter was 3.4 (0.1–12) cm. The mean tumor diameter
in DCIS group was 1.025 (0.5–1.5) cm.
In our study, hormone receptor levels were low
and HER2 levels were high in the PD-IC group. In the
molecular subtype analyses, HER2 rich group was the
highest. In terms of molecular subtypes among the
deceased 10 patients, 2 patients were luminal A, 4 patients
were luminal B HER2 +, 3 patients were HER2 rich, and
one patient was triple negative. Six patients from DCIS
group had high nuclear grade, while only one case had low
nuclear grade. Comedo necrosis was detected in 3 of these
cases, and one case was noncomedo DCIS. All pathological
features are summarized in Table 2. None of the parameters
mentioned above was statistically significant when the two
groups were compared.
While distant metastasis occurred in two patients from
PD-IC group during the first and second years of their
follow-up, one patient from PD-DCIS group (external
consultation) developed metastatic lymph nodes with
perinodal invasion in the ipsilateral axilla 3 years after the
index operation (mastectomy + SLNB).
The median follow-up period was 47 months (range:
1–120 months). Of 39 IC patients, 10 (25.6%) died
during the follow-up period. Among the 7 patients with
the available data of the cause of death, 5 had metastatic
disease, one developed pneumonia during chemotherapy,
and one had a myocardial infarction. Mortality was not
observed in PD-DCIS group. Invasive carcinoma group
had a mean OS of 57.8 ± 6.6 months (95% CI: 44.8–70.8)
and median OS of 58 ± 9.5 months (95% CI: 39.2–76.7)
(Figure 1). According to univariate analysis, only the
tumor type was found to impact OS (p < 0.001) (Figure 2).
Invasive ductal carcinoma had poor OS when compared
with mixed type. Other clinicopathologic variables were
not indicators of prognosis.
4. Discussion
Paget’s disease is a rare condition with gradually decreasing
incidence [15]. Studies on PD are mostly the single-center
cohort or case series, except for SEER database studies;
therefore, results vary accordingly. On the other hand, it
was shown that invasive cancers accompanied by PD had
a more aggressive pathological character and had a worse
prognosis than invasive breast cancers without PD in most
studies [8,10,16,17].
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Table 2. Histopathologic characteristics of the tumors.
PD-DCIS
n = 7 (%)

PDn = 39 (%)

Grade 1

-

2 (5.1)

Grade 2

-

21 (53.9)

Grade 3

-

15 (38.5)

Unknown

-

1 (2.5)

Positive

2 (28.6)

11 (28.2)

Negative

5 (71.4)

28 (71.8)

Positive

0

14 (35.9)

Negative

7 (100)

25 (64.1)

Positive

5 (71.4)

25 (64.1)

Negative

1 (14.3)

13 (33.4)

Unknown

1 (14.3)

1 (2.5)

≤15

-

9 (23.1)

>15

-

22 (56.4)

Unknown

-

8 (20.5)

Luminal A

-

2 (5.1)

Luminal B HER 2 +

-

7 (18)

Luminal B HER 2 -

-

4 (10.2)

HER 2 rich

-

13 (33.4)

Triple negative

-

5 (12.8)

Unknown

-

8 (20.5)

pN0

6 (85.7)

8 (20.5)

pN1

0

12 (30.8)

pN2

0

10 (25.6)

pN3

0

8 (20.5)

Unknown

1 (14.3)

1 (2.6)

Characteristic
Tumor Grade

ER status

PR status

HER2 status

Ki-67 (%)

Molecular subtype

Lymphnode status

PD-DCIS = Paget’s disease-ductal carcinoma in situ; PD-IC =
Paget’s disease-invasive carcinoma; ER = estrogen receptor; PR =
progesterone receptor; HER2 = human epidermal growth factor
receptor 2.

Paget’s disease is frequently encountered in females, in
the 5th–6th decades of life [3,8,10,18]. In our study, the
mean age was 53.5 years. In addition, patients from the
DCIS group were younger than those in the IC group.

Although Helme et al., in their review, reported that
multifocality ranged between 21% and 80% in mastectomy
specimens, recent studies have shown that multifocality
and/or multicentricity rates are below 40% [2,19,20].
In our study, this rate was found to be 30.8% in the IC
group and 28.6% in the DCIS group. Some studies also
have reported that NAC localization of the tumor is more
common in the DCIS group than in the IC group [10,15].
Our study also supported this data since NAC localization
was detected 57.1% and 25.6% of the patients with DCIS
and IC, respectively.
In the past, mastectomy was accepted as the standard
surgical procedure with the view that patients diagnosed
with Paget’s disease may have multifocal/multicentric
disease or occult tumor foci located outside the nipple in
the breast tissue [10]. This approach has recently changed,
and BCS + RT is accepted as an effective local treatment
method in selected cases [2,3,5]. Additionally, SLNB is
also recommended instead of routine axillary dissection in
selected cases [3,15]. In our study, mastectomy (92.3%) in
the IC group and breast-conserving surgery (72.4%) in the
DCIS group were the most preferred methods. SLNB was
also performed in most of the cases with DCIS (71.5%).
All patients, who underwent BCS, NAC excision, and
biopsy, received adjuvant RT.
More than 90% of PD is associated with invasive cancer
and the most common type of invasive cancer is invasive
ductal cancer. Invasive lobular cancer was reported only in
four studies in the literature, and the other specific types of
breast cancer accounted for less than 10% [2]. In our study,
84.7% of the cases were invasive carcinoma, and among
them, 76.9% were invasive ductal carcinoma. In univariate
analysis, tumor type was the only significant parameter
affecting the OS. Like the previous studies, IDC was found
to be associated with poor prognosis [6,18,22]. Müjgan
et al. found that cancer-specific survival was significantly
worse for patients with invasive disease [4].
Wachter et al. emphasized that PD accompanying lowgrade DCIS was uncommon, while Chen et al. found that
some of DCIS cases accompanied by PD were associated
with high mortality by displaying invasive cancer behavior
[10,21]. In a study by Wong et al. [15], lymph node
metastases were detected in 4.1% of DCIS patients which
was due to an undetectable occult invasive cancer. In our
study, six of seven patients with DCIS had high nuclear
grade, and axillary lymph node metastasis was detected in
one patient (14.2%) during follow-up.
Grade 2 and 3 tumors have been detected in 83.4%–
100% of PD-IC cases [3,4,6,8-10,23]. This rate was 92.4%
in our study, which was consistent with the literature.
Studies have shown that in invasive breast cancers
accompanied by PD, hormone receptor positivity is lower
and HER2 positivity is 2 to 4 times higher than invasive
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Survival Function
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Figure 1. Kaplan–Meier curves for cumulative survival of the IC group.
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Figure 2. Kaplan–Meier survival plots according to tumor type.

cancers without PD [2,4,9,10]. Although low hormone
receptor (HR) positivity and high HER2 positivity have
been shown to be effective on prognosis in many studies,
there is also exceptional study showing that these factors do
not have any impact on prognosis [10]. ER, PR, and HER2
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were detected as positive in 28.2%, 35.9%, and 64.1% of
our cases in accordance with the literature, but their effects
on prognosis were not statistically determined.
Molecular subtype analysis has an important effect on
the choice of treatment and determining the prognosis
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Table 3. Molecular subtype analyses in PD-IC in the literature.
Molecular subtype, n (%)
HR+/Her2 -

HR+/Her2 +

HR-/Her2 +

HR-/Her2 -

Unkown

121 (30.5)

132 (33.2)

119 (30.0)

25 (6.3)

-

Lee et al.

3 (9.4)

4 (12.5)

22 (68.8)

3 (9.4)

-

Wu et al.3

139 (19.1)

129 (27)

115 (24.1)

28 (5.9)

66 (13.8)

Yao et al.

108 (3.5)

114 (3.7)

107 (3.5)

23 (0.8)

2695 (88.4)

40 (28)

47 (32.9)

49 (34.2)

7 (4.9)

-

Chen et al.

10

1

5

Wong et al.9
Arafah et al.

2 (10)

4 (20)

9 (45)

5 (25)

-

Wahcter et al.21

-

10 (50)

8 (40)

2 (10)

-

Sek et al.

1 (8)

1 (8)

10 (84)

-

-

Lester et al.

-

3 (30)

4 (40)

3 (30)

-

Present study

6 (15.3)

7 (18)

13 (33.4)

5(12.8)

8 (20.5)

24

25
26

PD-IC = Paget’s disease–invasive carcinoma; HR = Hormon receptor; HER2 = human epidermal growth factor
receptor 2.

of the disease. HER2 rich and triple negative groups
demonstrate aggressive clinical behavior. When the
literature on molecular subtypes indicate that HER2 rich
and Luminal B subgroups are predominantly higher in
patients with PD-IC (Table3) [21,24-26]. In our study,
most invasive cancers (79.5%) with the available data of
immune markers were HER2 positive (64.5%), and most
of them were hormone receptor negative (41.9%). 40% of
the metastatic cases and 42.8% of the patients who died
during the follow-up were in the HER2 rich group.
High rates of lymph node involvement, between 48%
and 69%, in PD accompanied by invasive cancer have been
reported [2]. The study of Wong et al. [9] has shown that
the presence of PD is a statistically significant marker for
axillary metastasis in invasive breast cancer. The higher
rate (76.9%) of lymph node metastasis in our study
compared to previous studies was attributed to the fact
that more than half of the patients in the IC group had
advanced stage tumor at first admission.

In conclusion, there was no statistically significant
difference in terms of clinicopathological features when
PD-DCIS and PD-IC were compared. In addition, the
current study displayed the tumor type as the only
parameter affecting OS in the IC group. On the other hand,
although it was not statistically significant, breast cancers
accompanied by PD were found to be predominantly high
grade and/or advanced stage tumors, HR negative and
HER2 positive. In our study, HER2 rich subtype was the
most frequently observed molecular subtype. In addition,
considering that we may encounter PD-DCIS cases more
frequently in the near future, a close follow-up in PD cases
accompanied by DCIS would be beneficial to prevent
locoregional recurrence.
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